A Variant PfCRT Isoform Can Contribute to Plasmodium Falciparum Resistance to the First-Line Partner Drug Piperaquine

Satish K. Dhingra, Devasha Redhi, Jill M. Combrinck, Tomas Yeo, John Okombo, Philipp P. Henrich, Annie N. Cowell, Purva Gupta, Matthew L. Stegman, Jonathan M. Hoke, Roland A. Cooper, Elizabeth Winzeler, Sachel Mok, Timothy J. Egan, David A. Fidock

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
Article numbere00303-17
JournalMBio
Volume8
Issue number3
StatePublished - May 1 2017
Externally publishedYes

Funding

This research was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award no. R01 AI50234 and R01 AI124678 to D.A.F., R01 AI71121 to J.M.H. and R.A.C., R01 AI110329 to T.J.E., and R01 AI103058 to E.A.W. and D.A.F. Devasha Redhi and Jill Combrinck thank the National Research Foundation South Africa for scholarship support. We also thank Tree Star, Inc., for their donation of a 1-year subscription to FloJo version 10 analysis software. The authors declare they have no conflicts of interest.

FundersFunder number
Tree Star, Inc.
National Institutes of HealthR01 AI110329, R01 AI124678, R01 AI71121, R01 AI50234
National Institute of Allergy and Infectious DiseasesR01AI103058
National Research Foundation

    ASJC Scopus Subject Areas

    • Microbiology
    • Virology

    Keywords

    • Malaria
    • PfCRT
    • PLasmodium falciparum
    • Artemisinin-based combination therapies
    • Digestive vacuole
    • Genome editing
    • Heme detoxification
    • Piperaquine resistance
    • Plasmodium falciparum

    Disciplines

    • Biology
    • Parasitic Diseases
    • Pharmacology

    Cite this